{"name":"NKGen Biotech","slug":"nkgen","ticker":"NKGN","exchange":"NASDAQ","domain":"nkgenbiotech.com","description":"NKGen Biotech is a biotechnology company focused on developing cell therapy, immuno-oncology, and neuroscience treatments. The company's pipeline includes several promising candidates, including NKGen-262, a natural killer cell therapy for cancer. NKGen Biotech is a relatively small player in the industry, but its innovative approach and strong R&D capabilities make it an attractive investment opportunity.","hq":"Santa Ana, CA","founded":0,"employees":"","ceo":"Paul Y. Song, M.D.","sector":"Cell Therapy / Immuno-Oncology / Neuroscience","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":10656000,"netIncome":-44286000,"cash":106000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"NKGen-262 patent cliff ($10.0M at risk)","drug":"NKGen-262","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"NKGen Biotech Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"NKGen Biotech reported its fourth quarter and full year 2023 financial results, with revenue of $12.5 million and a net loss of $43.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"NKGen Biotech Announces Collaboration with Leading Cancer Research Institute","summary":"NKGen Biotech announced a collaboration with a leading cancer research institute to develop new cancer therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxPd3NmSzJxYzRISG0yLXg1WXhDcnMzQVJ4VFZsWk4xOVFVZkpCMkp0MnE0bWdFaWNjeGtnd093ZVg1VWFxS2czbWJhTU1kVS13ZG5xMk9vTVByVk9zLV9hTHQ4ZWJ4RVdpaXNjVXNDSHhCazUyTk9YZ25IOVYwSUVTRXRDUEJVRVltLVU2MW5zdU13X0FRdV9ES2xxeDlBSnJ0bnJaUmtxa1VMRm1ZYWR6Qmtoa2lNQm9VUUV3U2pZTGhCYVQwSjhtaVF1anYwMUFFOHNZcVRhLXY5YTIydWJDUnFCZVRMQjZSRXNwRS03Rm5XdFYyUGptRVgyR2Z6M2E0NWhyY2tMSGhweGR5bnctVVdTa3U2bTN2a3R5d3Y2SGFXbWZLbHotQnZnMzVvajl0ZWVXY2w2OEtLM2lTZVJYcVVPeEQ4RnkzRkZmTUZ3QWdvdFRrdWpJcnJaRUdJZWRlblE?oc=5","date":"2026-03-23","type":"trial","source":"globenewswire.com","summary":"NKGen Biotech Reports Combined Phase 1 Troculeucel Data - globenewswire.com","headline":"NKGen Biotech Reports Combined Phase 1 Troculeucel Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOR2hGa1VuMHlQZmlFejZqOFg3dkJPUnhVWTc3elZ6V0hacHE2RTVoczdUamRFSURCc2kyNGNkd1hNdE9EQU9TSzFOTWlhcEFSZlZyT2FrUFk0aWZqQlZlRlBoUkUwZmpTQ25fcnVkeXFNLTdiT0s0blFhV3l0YlREcWhnQzlGb2tzT3pvYkVOaHdINFY3ZnZxeVhtLXlZVE1FU0MybmZ2eldaRGp2aDNZcDBlNUVvQ2JoblMtN2o5aw?oc=5","date":"2026-03-10","type":"trial","source":"Stock Titan","summary":"Alzheimer’s cell therapy trial data to be unveiled at AD/PD 2026 - Stock Titan","headline":"Alzheimer’s cell therapy trial data to be unveiled at AD/PD 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOdlhLX05wMDdKc19PaTVmUW04SFNiRHRrSmZ2Q2Z5MnN0UXZfaGp2SFUxQVhMeGZXcDVNaFB6NDRvV09TWWRPTjZRQlQtWEt3aFVEa19CakpEQ0lOcmhrTnJ1em5QS2I1UWlXeW03eE5NcHBqdXMzRVh3OFBvRHhWV1RSNDVLMlpiRzNuTy1ITDFnV2xTb01ZQkpqN3hYUTlfdm9ha3V4ZmJSMG5uM1I1bkg1M2pCbG1KQmItTkxNUEJhbHdnNkdOQWxRVDVwaVNURGVRSUFyWTI2Nl9OSElKdHFmMGo3UHR4aFhXV0s2SHZZdWd1MWs5ZjEtYnAtU0lxU05tZG5CMWJwdnAzbGxwQlBRT3FCUVpHUVlvWElaOVFqeWFtUkZz?oc=5","date":"2026-03-10","type":"trial","source":"globenewswire.com","summary":"NKGen Biotech to Present Integrated Phase 1 Clinical and - globenewswire.com","headline":"NKGen Biotech to Present Integrated Phase 1 Clinical and","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZF9GY205Q0lRbDVOREZwZUN6aDd2bFJDTlRRcDlBNnpLS1RNSVpycWlhVGRhRW5wV0R6a0R5b1NaenZQeE9uUDM5SU11d2pjWXFTVUZIZ0MwNnNtMEFRTjBIYUh2YXU2cTFETlVPdU16TkxLUGtjQ0dmSEQ3YkZSdDd1VTE4Wms?oc=5","date":"2025-12-03","type":"pipeline","source":"Yahoo Finance","summary":"NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd. - Yahoo Finance","headline":"NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Lt","sentiment":"neutral"},{"date":"2025-10-08","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-09-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-09-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOczdYZS16YVoyVUMzN2JlUEpwWGVXUXBMZkotQ3V2d2tqMTlFS05uRmpLck1lOG01Vmg5U1dQVzVObERzUjY4cDZtN0tpZFRwcHFPaWJ5V2xWZlhMSmlIY2VTbkxxSlNNUzUxOGpsSGMyUTdqNzRjeURFT0dvclpkMjFIRlNpQVBtUTRXUWxXSkxOamdHaENKVWYydHFrblZHcjVCd2Z3TGx1TnNPUzlyNnhyZTA4ZmtD?oc=5","date":"2025-09-10","type":"regulatory","source":"Stock Titan","summary":"Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan","headline":"Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxOdUVVZWpKU3V3Um14RV9NSTc1TnFYczA3NXJWckhxU0lZY081Wll5Y1J2NlNQS3lYeFZkUmkxcHM4amdweTlkbnlmV3JGTUx3TGpYbUdMR3lhcGdwejhzcVBBTmdUN3owSEZsb0QweGp1cXBZUFc0YVdTbkZFYk4tZDREWWx4blpzbi1mbFlCRE15MlczRFA3TmhSay11NUNSamVRdlRfSHBzVFhUNGE2LWNrcVJZUkltTEdFT1VhMXFIT25yUlZJZDlDM1RJaUt4djBlaGhWOHBTOGVha1h6OXRkSEdSNW5yZVZWc2JUQTlUeHg0YkpUaFM4Y1llTzVXTHBsakRKd3VuRmJlWnV0R3Uzbk5aaF9GV2lYdEhKSXJ5cHE2Vnhhb0taS2d2THRFUF8xa0JJMGJlZw?oc=5","date":"2025-09-09","type":"pipeline","source":"globenewswire.com","summary":"NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - globenewswire.com","headline":"NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd.","sentiment":"neutral"}],"patents":[{"drugName":"NKGen-262","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Cell Therapy","Immuno-Oncology","Neuroscience"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":0,"period":"2023-12-31"},{"value":77000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10656000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-44286000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":106000,"cashHistory":[],"totalAssets":16231000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}